Vapotherm (NYSE:VAPO) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Vapotherm (NYSE:VAPO) from a hold rating to a buy rating in a report issued on Friday, Zacks.com reports. They currently have $18.00 price target on the stock.

According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute breathing disorders. The Company provides flow vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “

VAPO traded down $0.63 during midday trading on Friday, hitting $14.55. The company’s stock had a trading volume of 1,418,787 shares, compared to its average volume of 44,681. The company has a current ratio of 5.22, a quick ratio of 5.34 and a debt-to-equity ratio of 1.42. The firm has a market capitalization of $281.57 million and a price-to-earnings ratio of -1.05. The firm has a 50-day simple moving average of $20.08. Vapotherm has a 52-week low of $13.94 and a 52-week high of $24.63.

Vapotherm (NYSE:VAPO) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05. The business had revenue of $11.99 million during the quarter, compared to analysts’ expectations of $11.90 million. On average, sell-side analysts forecast that Vapotherm will post -3.1 earnings per share for the current fiscal year.

In other news, CEO Joseph Army acquired 15,000 shares of Vapotherm stock in a transaction dated Friday, August 2nd. The shares were acquired at an average cost of $14.28 per share, with a total value of $214,200.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 34.40% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Investors Inc. PA lifted its stake in shares of Vapotherm by 32.8% in the 1st quarter. Federated Investors Inc. PA now owns 398,435 shares of the company’s stock valued at $7,829,000 after purchasing an additional 98,435 shares in the last quarter. BlackRock Inc. acquired a new position in Vapotherm during the 4th quarter worth approximately $6,248,000. Northern Trust Corp acquired a new position in Vapotherm during the 4th quarter worth approximately $1,156,000. Geode Capital Management LLC acquired a new position in Vapotherm during the 4th quarter worth approximately $1,041,000. Finally, Granite Investment Partners LLC acquired a new position in Vapotherm during the 1st quarter worth approximately $811,000. 47.13% of the stock is currently owned by institutional investors and hedge funds.

About Vapotherm

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

See Also: Oversold

Get a free copy of the Zacks research report on Vapotherm (VAPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.